Zhi Chen

Zhi Chen inquired about BeOne Medicines' strategy for its emerging immunology pipeline, seeking elaboration on the path to becoming a meaningful player beyond hematology and solid tumors.

Answer

Lai Wang, President and Global Head of R&D, explained that approximately 20% of their preclinical assets are focused on immunology. The goal is to identify one or two first-in-class or best-in-class cornerstone assets for pivotal studies within the next 2-3 years, with some already in clinical stages.